arGEN-X Mutual Funds | StatInvestor

Health Care & Life Sciences » Biotechnology | arGEN-X

arGEN-X N.V. | Mutual Funds

Mutual Funds that own arGEN-X N.V.

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Federated Kaufmann Fund

1,793,314

5.53%

2.47%

06/29/2018

Oppenheimer International Small Company Fund

522,655

1.61%

-95,838

0.46%

02/28/2018

BB Biotech AG

396,819

1.22%

396,819

0.89%

03/31/2018

Government Pension Fund - Global (The)

259,999

0.8%

12/31/2017

Federated Kaufmann Small Cap Fund

253,560

0.78%

1.47%

06/29/2018

HBM BioVentures Ltd.

250,000

0.77%

1.58%

12/31/2017

JPMorgan Funds - Global Healthcare Fund

239,006

0.74%

-13,783

0.75%

05/31/2018

Stichting Pensioenfonds ABP (Global Equity Portfolio)

168,711

0.52%

114,657

03/31/2018

118,449

0.37%

91,933

2.79%

07/31/2018

Candriam Equities L - Biotechnology

104,401

0.32%

3,400

0.72%

07/31/2018

About arGEN-X

View Profile

Address	Willemstraat 5 Breda Noord-Brabant 4811 AH Netherlands
Employees	-
Website	http://www.argen-x.com
Updated	07/08/2019
argenx SE is a clinical-stage biotechnology company, which engages in the research and development of human monoclonal antibodies for the treatment of cancer and oncological, autoimmune, and inflammatory diseases. Its products include ARGX-113 for severe autoimmune diseases and ARGX-110 for T-cell lymphoma and acute myeloid leukemia. It operates through the following geographical segments: Netherlands, Belgium, Germany, Denmark, Switzerland, United States, and Luxemburg.